Source: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-cand-3_18-cv-00355/USCOURTS-cand-3_18-cv-00355-0/pdf.json

Nature of Suit Code: 890
Nature of Suit: Other Statutory Actions
Cause of Action: 15:1125 Trademark Infringement (Lanham Act)

---

1 

 STIPULATION AND [PROPOSED] ORDER TO SEVER CLAIMS 

CASE NO. 17-CV-06731-RS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Don J. Mizerk, Esq. (SBN: 208477) 

Husch Blackwell LLP 

120 South Riverside Plaza 

Chicago, Illinois 60606 

Tel: (312) 526-1546 

Fax: (312) 655-1501 

don.mizerk@huschblackwell.com 

Attorney for Defendants

VIRTUS PHARMACEUTICALS, LLC 

VIRTUS PHARMACEUTICALS OPCO II, LLC 

BELCHER PHARMACEUTICALS, LLC 

Gina E. Och

Murchison and Cumming, LLP 

801 South Grand Avenue, 9th Floor

Los Angeles, CA 90017

Tel: (213) 623-7400

Fax: (213) 623-6336

Email: goch@murchisonlaw.com 

Attorney for Defendants 

BI-COASTAL PHARMA INTERNATIONAL LLC 

BI-COASTAL PHARMACEUTICALS CORPORATION 

Jean P. Nogues, Jr.

Mitchell Silberberg and Knupp 

11377 W Olympic Blvd 

Los Angeles, CA 90064

(310) 312-2000

Email: jpn@msk.com

Attorney for Defendant

ECI PHARMACEUTICALS LLC 

UNITED STATES DISTRICT COURT 

NORTHERN DISTRICT OF CALIFORNIA 

SAN FRANCISCO DIVISION 

VALEANT PHARMACEUTICALS NORTH 

AMERICA, LLC, 

Plaintiff, 

v.

BELCHER PHARMACEUTICALS, LLC, BICOASTAL PHARMACEUTICAL 

CORPORATION, BI-COASTAL PHARMA 

INTERNATIONAL LLC, ECI 

PHARMACEUTICALS LLC, VIRTUS 

PHARMACEUTICALS, LLC and VIRTUS 

PHARMACEUTICALS OPCO II, LLC, 

Defendants.

Case No. 17-CV-06731-RS 

STIPULATION AND [PROPOSED] 

ORDER TO SEVER CLAIMS AGAINST: 

(1) BI-COASTAL PHARMACEUTICAL 

CORPORATION AND BI-COASTAL 

PHARMA INTERNATIONAL LLC; AND 

(2) ECI PHARMACEUTICALS LLC 

FROM THIS ACTION INTO SEPARATE 

CASES 

Case 3:18-cv-00355-RS Document 34 Filed 01/16/18 Page 1 of 5
 2 

 STIPULATION AND [PROPOSED] ORDER TO SEVER CLAIMS 

CASE NO. 17-CV-06731-RS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Pursuant to Federal Rule of Civil Procedure Rule 21 and Civil Local Rule 7-12, all 

Parties to the above-entitled action, by and through their undersigned counsel, hereby stipulate to 

the following and respectfully request that the Court enter an Order severing into separately 

captioned actions all claims made by Plaintiff against, respectively: (1) Bi-Coastal

Pharmaceutical Corporation and Bi-Coastal Pharma International LLC; and (2) ECI 

Pharmaceuticals LLC. For clarity, the intent of the Parties’ Stipulation and [Proposed] Order is 

to sever the claims made by Plaintiff, without prejudice, against the three groups of current 

Defendants into three separately captioned actions as follows:

(1) all claims made by Plaintiff against: (a) Belcher Pharmaceuticals, LLC; (b) 

Virtus Pharmaceuticals, LLC; and (c) Virtus Pharmaceuticals OPCO II, LLC would 

remain in this action, Case No. 17-CV-06731-RS; 

(2) all claims made by Plaintiff against Bi-Coastal Pharmaceutical Corporation 

and Bi-Coastal Pharma International LLC would be severed into a new action captioned 

Valeant Pharmaceuticals North America LLC v. Bi-Coastal Pharmaceutical Corporation 

and Bi-Coastal Pharma International LLC;

(3) all claims made by Plaintiff against ECI Pharmaceuticals LLC would be 

severed into a new action captioned Valeant Pharmaceuticals North America LLC v. ECI 

Pharmaceuticals LLC.

The Parties respectfully submit that this Stipulation and [Proposed] Order will not result 

in prejudice at this early stage in the proceedings and will promote fundamental fairness and 

judicial efficiency. The parties further undertake to make good faith efforts to coordinate 

discovery and its timing in the three cases, including written discovery and depositions, to the 

extent reasonably practicable so long as no material prejudice is caused to any Party by such 

coordination.

 NOW THEREFORE, in order to effectuate the Parties’ intent as set forth herein, all 

Parties, by and through their respective counsel, hereby stipulate as follows: 

Case 3:18-cv-00355-RS Document 34 Filed 01/16/18 Page 2 of 5
 3 

 STIPULATION AND [PROPOSED] ORDER TO SEVER CLAIMS 

CASE NO. 17-CV-06731-RS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

 (1) All claims made by Plaintiff against, respectively: (a) Bi-Coastal Pharmaceutical 

Corporation and Bi-Coastal Pharma International LLC; and (b) ECI Pharmaceuticals LLC are 

hereby SEVERED from this action, Case No. 17-CV-06731-RS into two new cases defined in 

paragraphs (2) and (3) below; 

(2) all claims made by Plaintiff against Bi-Coastal Pharmaceutical Corporation and BiCoastal Pharma International LLC are severed from Case No. 17-CV-06731-RS and placed into 

a new action captioned Valeant Pharmaceuticals North America LLC v. Bi-Coastal 

Pharmaceutical Corporation and Bi-Coastal Pharma International LLC, which claims shall be 

set forth in an amended complaint as described in paragraph (5) below; 

(3) all claims made by Plaintiff against ECI Pharmaceuticals LLC are severed from Case 

No. 17-CV-06731-RS and placed into a new action captioned Valeant Pharmaceuticals North 

America LLC v. ECI Pharmaceuticals LLC, which claims shall be set forth in an amended 

complaint as described in paragraph (5) below; 

(4) all claims made by Plaintiff against: (a) Belcher Pharmaceuticals, LLC; (b) 

Virtus Pharmaceuticals, LLC; and (c) Virtus Pharmaceuticals OPCO II, LLC remain in this Case 

No. 17-CV-06731-RS, which claims shall be set forth in an amended complaint as described in 

paragraph (5) below; and 

(5) In accordance with the above severance of claims: 

(a) Plaintiff is directed within fourteen (14) days of entry of the Court’s Order 

granting the stipulated severances and receipt of new case numbers for the severed 

actions to file an amended complaint in each of the three actions described above setting 

forth allegations applicable to the respective Defendants in that particular case; 

(b) Each of the Defendants in the three separate actions described above is 

directed to file a responsive pleading within twenty-one (21) days after Plaintiff files its 

amended complaint in that action; 

(c) All current deadlines in the present action shall be extended by twenty-one 

(21) days, and such extension shall apply in each of the three separate cases described 

above.

Case 3:18-cv-00355-RS Document 34 Filed 01/16/18 Page 3 of 5
 4 

 STIPULATION AND [PROPOSED] ORDER TO SEVER CLAIMS 

CASE NO. 17-CV-06731-RS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

(d) The parties shall make good faith efforts to coordinate discovery and its 

timing in the three cases described above, including written discovery and depositions, to 

the extent reasonably practicable so long as no material prejudice is caused to any Party 

by such coordination. 

Dated: January 15, 2018 

ROPES & GRAY LLP 

By:___/s/ Rocky Tsai_______________

 Rocky Tsai, Esq. (CSB No. 221452) 

Attorney for Plaintiff, Valeant 

Pharmaceuticals North America LLC 

Three Embarcadero Center 

San Francisco, California 94111 

Tel: (415) 315-6300 

Fax: (415) 315-6350 

rocky.tsai@ropesgray.com

HUSCH BLACKWELL LLP 

By:___/s/ Don J. Mizerk________________

 Don J. Mizerk, Esq. (SBN: 208477) 

Attorney for Defendants Belcher 

Pharmaceuticals, LLC, Virtus Pharmaceuticals 

LLC, and Virtus Pharmaceuticals OPCO II, LLC

120 South Riverside Plaza, Suite 2200 

Chicago, Illinois 60606 

Tel: (312) 526-1546 

Fax: (312) 655-1501 

don.mizerk@huschblackwell.com

MURCHINSON AND CUMMING, LLP 

By:___/s/ Gina E. Och________________

 Gina E. Och (SBN:170520) 

Attorney for Bi-Coastal Pharma International 

LLC and Bi-Coastal Pharmaceuticals 

Corporation

801 South Grand Avenue, 9th Floor

Los Angeles, CA 90017

Tel: (213) 623-7400

Fax: (213) 623-6336

Email: goch@murchisonlaw.com

MITCHELL SILBERBERG AND KNUPP 

By:___/s/ Jean P. Nogues, Jr.____________ Jean P. Nogues, Jr. (SBN: 84445) 

Attorney for Defendant ECI Pharmaceuticals 

LLC

11377 W Olympic Blvd 

Los Angeles, CA 90064

(310) 312-2000

Email: jpn@msk.com

Case 3:18-cv-00355-RS Document 34 Filed 01/16/18 Page 4 of 5
 5 

 STIPULATION AND [PROPOSED] ORDER TO SEVER CLAIMS 

CASE NO. 17-CV-06731-RS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

[PROPOSED] ORDER 

PURSUANT TO STIPULATION, IT IS SO ORDERED. 

Dated: ________________, 2018 _______________________________________ 

United States District Judge 

CERTIFICATE OF SERVICE 

The undersigned counsel for Defendants Virtus Pharmaceuticals LLC and Virtus 

Pharmaceuticals OPCO II, LLC, hereby certifies that on January 15, 2018, a true and correct 

copy of the foregoing STIPULATION AND [PROPOSED] ORDER TO SEVER CLAIMS 

AGAINST: (1) BI-COASTAL PHARMACEUTICAL CORPORATION AND BICOASTAL PHARMA INTERNATIONAL LLC; AND (2) ECI PHARMACEUTICALS 

LLC FROM THIS ACTION INTO SEPARATE CASES was filed with the Court and served 

electronically by the Court’s CM/ECF System to all registered users. 

 /s/ Don J. Mizerk 

Attorney for Defendants Virtus Pharmaceuticals 

LLC, and Virtus Pharmaceuticals OPCO II, LLC 

1/16

Case 3:18-cv-00355-RS Document 34 Filed 01/16/18 Page 5 of 5